Aurobindo Pharma · NSE: AUROPHARMA · BSE: 524804
Q3 FY19 results · Oct–Dec 2018
Aurobindo Pharma reported revenue from operations of ₹5,269.67 crore and net profit of ₹712.21 crore for Q3 FY19 (Oct–Dec 2018), on a consolidated basis.
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 5,269.67 | — | — | 4,751.40 | +10.9% |
| Other income | 63.85 | — | — | 26.26 | +143.1% |
| Total income | 5,333.52 | — | — | 4,777.66 | +11.6% |
| Profit before share of associates & JVs and tax | 914.42 | — | — | 786.62 | +16.2% |
| Share of profit/(loss) of associates & JVs | 2.57 | — | 0.24 | ||
| Net profit for the period | 712.21 | — | — | 611.44 | +16.5% |
| Attributable to shareholders of the company | 538.77 | — | — | 803.06 | −32.9% |
| EPS, basic (₹) | 12.15 | — | — | 10.44 | +16.4% |
| Net margin (%) | 13.5 | — | 12.9 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,248.10 | — | — | 3,170.39 | +2.5% |
| Other income | 136.87 | — | — | 4.18 | 33x |
| Total income | 3,384.97 | — | — | 3,174.57 | +6.6% |
| Profit before tax | 584.68 | — | — | 479.41 | +22.0% |
| Net profit for the period | 463.51 | — | — | 380.95 | +21.7% |
| EPS, basic (₹) | 7.91 | — | — | 6.50 | +21.7% |
| Net margin (%) | 14.3 | — | 12.0 |
Consolidated
- Filed with BSE
- 08 Feb 2019, 12:28 IST
- Board meeting
- 07 Feb 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Feb 2019, 12:28 IST
- Board meeting
- 07 Feb 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE